and anxiety, increasing flexibility, and reducing the need for informal care and the burden on informal caregivers); labour market participation and productivity (increasing labour market participation, retaining skills and improving productivity). uterine artery/fibroid embolisation (ufe) in 2011 the mtg and patient support group femisa published a report, the provision of and access to uterine artery/fibroid, a less invasive treatment for fibroids for women. the report, which was welcomed by the british society of interventional radiologists, highlighted a lack of coherent commissioning in england, despite national institute for health and care excellence clinical guidelines recommending ufe as a first-line treatment for symptomatic fibroids. insulin pump provision in 2010 the mtg made a freedom of information request to primary care trusts in england on the provision of insulin pumps to patients with type 1 diabetes. it found the average to be 3.9 per cent compared to the 12 per cent benchmark recommended by the national institute for health and clinical excellence. the findings were the subject of an early day motion tabled by adrian sanders mp on 9 december 2010. medical technology in 2004, the mtg's report making the economic case for medical technology suggested that increasing the provision of medical technology can "help patients better manage their conditions" and lead a "longer and relatively healthy life". it also suggested that by making greater use of technology there are cost benefits for the national health service. the report was the subject of an early day motion tabled by ian gibson mp. the motion was signed by 30 members of parliament. organisation the mtg is chaired by barbara harpham, former national director of heart research uk. she has been quoted as saying that the uk lags behind other european countries in the take-up of medical technology.